Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
Buprenorphine & naloxone
Form:
10 of 10 products shown
All strengths: General benefit; same patient cost rules
Shared coverage and patient cost rules
StatusGeneral benefit
Patient paysODB senior: $100/program-year deductible
• Then up to $6.11 per prescription
Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription
Free naloxone kits in Ontario: no prescription or health card needed; free kits at participating pharmacies and community sites
Free naloxone kits: eligibility and accessBrand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Buprenorphine/Naloxone · DIN 02453908
Manufacturer: Actavis Pharma Company; listing date 2018-01-31
Health Canada: Marketed since 2021-03-22 · brand TEVA-BUPRENORPHINE/NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Act Buprenorphine/Naloxone: Formulary list price $1.34 per unit (the source does not state the unit; exact figure $1.3350). What the ministry pays, not the patient.
DIN 02453908: Act Buprenorphine/Naloxone
Raw flags: sec3=Y
Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id ACV
Source form: SL Tab; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3350; ministry $1.3350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453908
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94043Interchangeable products
PMS-Buprenorphine-Naloxone · DIN 02424851 · $1.3350
Suboxone · DIN 02295695 · $1.3350
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453908
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Buprenorphine-Naloxone · DIN 02424851
Manufacturer: Pharmascience Inc.; listing date 2015-02-26
Health Canada: Marketed since 2017-11-24 · brand PMS-BUPRENORPHINE-NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 0.5 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-Buprenorphine-Naloxone: Formulary list price $1.34 per unit (the source does not state the unit; exact figure $1.3350). What the ministry pays, not the patient.
DIN 02424851: PMS-Buprenorphine-Naloxone
Raw flags: sec3=Y
Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id PMS
Source form: SL Tab; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $1.3350; ministry $1.3350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424851
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90952Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453908 · $1.3350
Suboxone · DIN 02295695 · $1.3350
Shortage status: resolved shortage (ended October 4, 2024); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424851
DIN 02295695: Suboxone
Raw flags: sec3=Y
Item: 280812006; group id 415; item number 1021; lccId None; manufacturer id IND
Source form: SL Tab; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $2.7261; ministry $1.3350
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295695
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78104Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453908 · $1.3350
PMS-Buprenorphine-Naloxone · DIN 02424851 · $1.3350
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295695
Shortage record checked October 6, 2026
Suboxone · DIN 02502313 · 2 mg & 0.5 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502313
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 2 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 0.5 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502313: Suboxone
Raw flags: sec3=Y
Item: 280812032; group id 415; item number 1023; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 2mg & 0.5mg
Recorded listing: General benefit
Source prices (unrounded): $2.6700; ministry $2.6700
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502313
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99189
Shortage status: resolved shortage (ended April 28, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502313
Shortage record checked October 6, 2026
Suboxone · DIN 02502321 · 4 mg & 1 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502321
Manufacturer: Indivior UK Limited; listing date 2026-02-27
Health Canada: Marketed since 2021-06-17 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 4 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 1 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502321: Suboxone
Raw flags: sec3=Y
Item: 280812033; group id 415; item number 1024; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 4mg & 1mg
Recorded listing: General benefit
Source prices (unrounded): $3.6889; ministry $3.6889
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502321
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99190
Shortage status: resolved shortage (ended July 4, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502321
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Act Buprenorphine/Naloxone · DIN 02453916
Manufacturer: Actavis Pharma Company; listing date 2018-01-31
Health Canada: Marketed since 2021-03-22 · brand TEVA-BUPRENORPHINE/NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG · company Teva canada limited · schedule Narcotics (cdsa i)
Act Buprenorphine/Naloxone: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3650). What the ministry pays, not the patient.
DIN 02453916: Act Buprenorphine/Naloxone
Raw flags: sec3=Y
Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id ACV
Source form: SL Tab; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $2.3650; ministry $2.3650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02453916
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=94044Interchangeable products
PMS-Buprenorphine-Naloxone · DIN 02424878 · $2.3650
Suboxone · DIN 02295709 · $2.3650
Shortage status: resolved shortage (ended April 8, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02453916
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
PMS-Buprenorphine-Naloxone · DIN 02424878
Manufacturer: Pharmascience Inc.; listing date 2015-02-26
Health Canada: Marketed since 2017-11-24 · brand PMS-BUPRENORPHINE-NALOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG · company Pharmascience inc · schedule Narcotics (cdsa i)
PMS-Buprenorphine-Naloxone: Formulary list price $2.37 per unit (the source does not state the unit; exact figure $2.3650). What the ministry pays, not the patient.
DIN 02424878: PMS-Buprenorphine-Naloxone
Raw flags: sec3=Y
Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id PMS
Source form: SL Tab; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $2.3650; ministry $2.3650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02424878
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=90953Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453916 · $2.3650
Suboxone · DIN 02295709 · $2.3650
Shortage status: resolved shortage (ended January 16, 2022); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02424878
Shortage record checked October 6, 2026
Suboxone · DIN 02295709 · 8 mg & 2 mg · SL tablet
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
1 brand, same coverage
Suboxone · DIN 02295709
Manufacturer: Indivior UK Limited; listing date 2012-10-30
Health Canada: Marketed since 2016-04-01 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Tablet · route Sublingual · ingredients NALOXONE (NALOXONE HYDROCHLORIDE DIHYDRATE) 2 MG, BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02295709: Suboxone
Raw flags: sec3=Y
Item: 280812010; group id 415; item number 1022; lccId None; manufacturer id IND
Source form: SL Tab; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $4.8293; ministry $2.3650
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02295709
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=78105Interchangeable products
Act Buprenorphine/Naloxone · DIN 02453916 · $2.3650
PMS-Buprenorphine-Naloxone · DIN 02424878 · $2.3650
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295709
Shortage record checked October 6, 2026
Suboxone · DIN 02502348 · 8 mg & 2 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502348
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 8 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 2 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502348: Suboxone
Raw flags: sec3=Y
Item: 280812034; group id 415; item number 1025; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 8mg & 2mg
Recorded listing: General benefit
Source prices (unrounded): $4.7300; ministry $4.7300
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502348
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99191
Shortage status: resolved shortage (ended May 18, 2023); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502348
Shortage record checked October 6, 2026
Suboxone · DIN 02502356 · 12 mg & 3 mg · Soluble Film
General benefitMarketed · checked October 5, 2026
Write on scriptno code needed
No interchangeable product listed in the Ontario extract
Suboxone · DIN 02502356
Manufacturer: Indivior UK Limited; listing date 2024-05-31
Health Canada: Marketed since 2021-01-20 · brand SUBOXONE · ATC N07BC51 BUPRENORPHINE, COMBINATIONS, N07BC51 BUPRENORPHINE, COMBINATIONS · form Film (soluble) · route Buccal, Sublingual · ingredients BUPRENORPHINE (BUPRENORPHINE HYDROCHLORIDE) 12 MG, NALOXONE (NALOXONE HYDROCHLORIDE) 3 MG · company Indivior uk limited · schedule Narcotics (cdsa i)
DIN 02502356: Suboxone
Raw flags: sec3=Y
Item: 280812031; group id 415; item number 1026; lccId None; manufacturer id IND
Source form: Soluble Film; strength: 12mg & 3mg
Recorded listing: General benefit
Source prices (unrounded): $7.0950; ministry $7.0950
Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02502356
Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=99192
Shortage status: no shortage or discontinuation reported (checked October 6, 2026); reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02502356
Shortage record checked October 6, 2026
Other products in the same Health Canada class (N07BC): coverage varies; not interchangeable
Buprenorphine (Sublocade): general benefit
Buprenorphine (Probuphine): limited Use 578
Other drugs in the same formulary class (28:08:12 Opiate Partial Agonists) and how they are covered
Matched class: 28:08:12 Opiate Partial Agonists
Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment.
Public program routes: ODB 65 and over
Covered without a code on the Ontario formulary: BUPRENORPHINE
28:08:12 Opiate Partial Agonists
1 INDICATIONS
SUBOXONE® (buprenorphine and naloxone) is indicated for:
• substitution treatment in adults with problematic opioid drug dependence.
1.1 Pediatrics
Pediatrics (<18 years of age): Based on the data submitted and reviewed by Health Canada, the
safety and efficacy of SUBOXONE in pediatric patients has not been established; therefore,
Health Canada has not authorized an indication for pediatric use.
1.2 Geriatrics
Geriatrics (> 65 years of age): The safety and efficacy of SUBOXONE have not been established
in adults over 65 years of age.
In general, dose selection for an elderly patient should be cautious, usually starting at the low
end of the dosing range, reflecting the greater frequency of decreased hepatic, renal,
respiratory or cardiac function, concomitant disease or other drug therapy.
https://pdf.hres.ca/dpd_pm/00069997.PDF
PM date: MAY 17, 2007
Source product: SUBOXONE; DIN 02295695; fetched 2026-09-10
Product monograph posted by Health Canada; excerpt for lookup only.
Availability
Suboxone · DIN 02295695
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295695
Suboxone · DIN 02295709
Shortage status: To be discontinued; reports as of October 6, 2026 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02295709
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules):
ODB 65 and over (seniors path)
Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗)
Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗)
Eligibility: Individual annual net income threshold
Program year August 1, 2026 to July 31, 2027: $25,480
This applies to a senior who:
does not have a spouse
has a married spouse with whom they no longer live in a conjugal relationship
has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗)
Eligibility: Combined annual net income requirement
Program year August 1, 2026 to July 31, 2027: $42,290
This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗)
Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗)
What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗)
What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗)
Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗)
Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100.
That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year).
For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25.
Use this chart below to see what the deductible will be in your first year: